Cantuzumab ravtansine

Cat. No.:	HY-P99493
CAS No.:	868747-45-9
Target:	Antibody-Drug Conjugates (ADCs); Microtubule/Tubulin
Pathway:	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].
In Vitro	Cantuzumab ravtansine (huC242-DM4; 5 days) shows cytotoxic effect in CanAg-positive SNU16 gastric cancer cells[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cantuzumab ravtansine (huC242-DM4; i.v; 3.4 mg/kg; a single dose) causes complete regression of the tumors in SCID mice bearing N87 human gastric tumor xenografts, with significant tumor regression observed at a dose below 2 mg/kg[1]. Cantuzumab ravtansine (huC242-DM4) is also curative in mice bearing human colon tumor xenografts of HT29 and COLO 205 cells, at doses that were non-toxic[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335.

[2]. Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement): A127.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA